GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ARIAD Pharmaceuticals Inc (NAS:ARIA) » Definitions » Cyclically Adjusted PS Ratio

ARIAD Pharmaceuticals (ARIAD Pharmaceuticals) Cyclically Adjusted PS Ratio : (As of May. 05, 2024)


View and export this data going back to 1994. Start your Free Trial

What is ARIAD Pharmaceuticals Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


ARIAD Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

The historical data trend for ARIAD Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ARIAD Pharmaceuticals Cyclically Adjusted PS Ratio Chart

ARIAD Pharmaceuticals Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ARIAD Pharmaceuticals Quarterly Data
Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ARIAD Pharmaceuticals's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, ARIAD Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ARIAD Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ARIAD Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where ARIAD Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.



ARIAD Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

ARIAD Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2016 is calculated as:

For example, ARIAD Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Sep. 2016 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Sep. 2016 (Change)*Current CPI (Sep. 2016)
=0.238/101.8610*101.8610
=0.238

Current CPI (Sep. 2016) = 101.8610.

ARIAD Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
200612 0.003 85.142 0.004
200703 0.003 86.640 0.004
200706 0.003 87.906 0.003
200709 0.023 87.964 0.027
200712 0.023 88.616 0.026
200803 0.022 90.090 0.025
200806 0.021 92.320 0.023
200809 0.022 92.307 0.024
200812 0.037 88.697 0.042
200903 0.025 89.744 0.028
200906 0.024 91.003 0.027
200909 0.021 91.120 0.023
200912 0.023 91.111 0.026
201003 0.020 91.821 0.022
201006 1.508 91.962 1.670
201009 0.011 92.162 0.012
201012 0.005 92.474 0.006
201103 0.000 94.283 0.000
201106 0.000 95.235 0.000
201109 0.183 95.727 0.195
201112 0.001 95.213 0.001
201203 0.001 96.783 0.001
201206 0.002 96.819 0.002
201209 0.001 97.633 0.001
201212 0.000 96.871 0.000
201303 0.036 98.209 0.037
201306 0.076 98.518 0.079
201309 0.090 98.790 0.093
201312 0.046 98.326 0.048
201403 0.063 99.695 0.064
201406 0.065 100.560 0.066
201409 0.078 100.428 0.079
201412 0.358 99.070 0.368
201503 0.128 99.621 0.131
201506 0.155 100.684 0.157
201509 0.154 100.392 0.156
201512 0.193 99.792 0.197
201603 0.187 100.470 0.190
201606 0.350 101.688 0.351
201609 0.238 101.861 0.238

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


ARIAD Pharmaceuticals  (NAS:ARIA) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


ARIAD Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of ARIAD Pharmaceuticals's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ARIAD Pharmaceuticals (ARIAD Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
ARIAD Pharmaceuticals Inc was organized as a Delaware corporation in April 1991. It is an oncology company. The Company is focused on discovery and development of breakthrough medicines to treat cancers by regulating cell signaling with small molecules. The Company's first approved cancer medicine, Iclusig (ponatinib), and its product candidates, AP26113 and ridaforolimus, were discovered internally by its scientists based on the expertise in computational and structure-based drug design. AP26113 is an investigational inhibitor of anaplastic lymphoma kinase, or ALK. In non-clinical studies, AP26113 also demonstrated that it can inhibit epidermal growth factor receptor, or EGFR, and c-ros oncogene-1, or ROS1. . Iclusig and its drug candidates and preclinical compounds are small molecules that can be readily synthesized by processes that it has developed. The Company do not own or operate manufacturing facilities for the production of clinical or commercial quantities of Iclusig or its product candidates. The company's competitors includes pharmaceutical and biotechnology companies such as Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, the Roche Group, GlaxoSmithKline plc, Johnson & Johnson, Merck, Merck KGaA, Novartis AG, Pfizer, Inc., Sanofi-Aventis, Takeda Pharmaceutical Co., Ltd., and Teva Pharmaceutical Industries Ltd.Inc.
Executives
Alexander J Denner director C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Norbert G Riedel director BAXTER INTERNATIONAL INC, ONE BAXTER PKWY DF2-1W, DEERFIELD IL 60015
Elona Esq. Kogan officer: Sr. V. P. - General Counsel C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Manmeet Singh Soni officer: EVP, CFO & Treasurer C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085
Timothy P Clackson officer: President, R&D, CSO C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Jules Haimovitz director 601 108TH AVENUE NE, SUITE 1200, BELLEVUE WA 98004
Daniel M Bollag officer: Sr. VP, Reg. Affairs & Quality C/O ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Hugh M Cole officer: SVP, Chief Business Officer C/O ARIAD PHARMACEUTICALS, INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
George Bickerstaff director C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Paris Panayiotopoulos director, officer: President and CEO ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Anna Protopapas director MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Sarah J. Schlesinger director C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Massimo Radaelli director C/O ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Martin J Duvall officer: EVP, CCO MGI PHARMA, INC., 5775 WEST OLD SHAKOPEE ROAD, SUITE 100, BLOOMINGTON MN 55437
Frank Haluska officer: SVP, Clinical R&D, CMO C/O ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139

ARIAD Pharmaceuticals (ARIAD Pharmaceuticals) Headlines

From GuruFocus